In Its SNP-Genotyping Biz, Illumina Shifts Focus from Higher-Density Arrays to Content

Illumina CEO Jay Flatley said the company sees limited benefit to introducing arrays that are more dense than the 1.2-million-marker Infinium HD Human 1M-Duo BeadChip, which it began shipping during the second quarter. Instead, future products are likely to be introduced on the basis of content or new, multi-sample formats.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.